1,2,3,4-Tetrahydroisoquinolines, processes for their preparation, and their use as kappa-receptor agonists
申请人:SmithKline Beecham Farmaceutici S.p.A.
公开号:EP0330360A1
公开(公告)日:1989-08-30
A compound, or a solvate or salt thereof, of formula (I):
in which:
RCO is an acyl group in which the group R contains a substituted or unsubstituted carbocyclic aromatic or heterocyclic aromatic ring and R₁ and R₂ are independently hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl or C₄₋₁₂ cycloalkylalkyl groups or together form a C₂₋₈ branched or linear polymethylene or C₂₋₆ alkenylene group optionally substituted with a hetero-atom;
R₃ is hydrogen, C₁₋₆ alkyl, or phenyl, or R₃ together with R₁ forms a -(CH₂)₃- or -(CH₂)₄-, group;
R₄ and R₅, which may be the same or different and may be attached to the same or different carbon atoms of the isoquinoline nucleus, are each hydrogen, halogen, hydroxy, C₁₋₆ alkyl, aryl, or R₄ together with R₅ form a -(CH₂)p- group, where p is an integer of from 1 to 5 and one or more of the -(CH₂)- moieties is optionally substituted by a C₁₋₆ alkyl group.
R₆ and R6a, which may be the same or different, are each hydrogen, C₁₋₆ alkyl, -CH₂OR6b, halogen, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, thiol, C₁₋₆ alkylthio,
-OR6c, -NHCOR6d, -NHSO₂R6e, -CH₂SO₂NR6fR6g, in which each of R6b to R6g is independently hydrogen, C₁₋₆ alkyl, aryl or aralkyl;
with the proviso that R₄, R₅, R₆ and R6a are not simultaneously hydrogen,
is useful for the treatment of pain.
一种式(I)化合物或其溶液或盐:
其中
RCO 是酰基,其中基团 R 含有取代或未取代的碳环芳香环或杂环芳香环,且 R₁ 和 R₂ 独立地为氢、C₁₋₆ 烷基、C₂₋₆ 烯基、C₃₋₆ 环烷基或 C₃₋₆ 环烷基、C₃₋₆环烷基或 C₄₋₁₂ 环烷基烷基,或共同形成 C₂₋₈支链或线性聚亚甲基或 C₂₋₆烯基,可选择被杂原子取代;
R₃ 是氢、C₁₋₆ 烷基或苯基,或 R₃ 与 R₁ 一起形成 -(CH₂)₃- 或 -(CH₂)₄- 基团;
R₄和 R₅可以相同或不同,可以连接到异喹啉核的相同或不同的碳原子上,它们各自是氢、卤素、羟基、C₁₋₆烷基、芳基,或 R₄ 与 R₅ 共同形成-(CH₂)p-基团,其中 p 为 1 至 5 的整数,且一个或多个-(CH₂)-基团可选地被 C₁₋₆ 烷基取代。
R₆ 和 R6a 可以相同或不同,各自为氢、C₁₋₆ 烷基、-CH₂ OR6b、卤素、羟基、C₁₋₆ 烷氧基、C₁₋₆ 烷氧羰基、硫醇、C₁₋₆ 烷硫基、
-OR6c、-NHCOR6d、-NHSO₂R6e、-CH₂SO₂NR6fR6g,其中 R6b 至 R6g 各自独立为氢、C₁₋₆烷基、芳基或芳烷基;
但 R₄、R₅、R₆ 和 R6a 不能同时为氢、
可用于治疗疼痛。